Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
Phase I Study Investigating the Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer With High and Moderate HER2 Expression
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Christoph Wiltschke, Prof
- Phone Number: +43 40400 4445
- Email: Christoph.Wiltschke@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Dept of Internal Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of metastatic breast cancer
- presence of at least 1 measurable lesion according to modified RECIST criteria
- Evidence (fluorescence in situ hybridization FISH) of
- Her-2 overexpression in tumor tissue:Group A: Her-2 +++, Group B: Her-2 + or ++
- EGFR-expressing disease as assessed by immunohistochemistry
- Recovered from relevant toxicities from other treatment prior to study entry
Exclusion Criteria:
- Prior treatment with trastuzumab for metastatic breast cancer (adjuvant therapy is allowed)
- Prior treatment with cetuximab
- Concomitant cytotoxic chemotherapy
- Treatment with any investigational agent(s) within 4 weeks prior to study entry
- Known allergic/hypersensitivity reaction to any of the components of study treatments
- severe dyspnea
- Myocardial infarction within 6 months prior to study entry, uncontrolled congestive heart failure; or any current grade 3 or 4 cardio-vascular disorder despite treatment
- History of significant neurologic or psychiatric disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics and drug/drug interaction of cetuximab and
Time Frame: repeated PK measurements week 1-13
|
repeated PK measurements week 1-13
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and tolerability of the combination treatment
Time Frame: week 1 -13
|
week 1 -13
|
|
Response
Time Frame: week 9 and 13
|
week 9 and 13
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christoph Zielinski, MD, Dept of Internal Medicine, Medical University Vienna
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CETRA 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.